Pathologists are increasingly challenged to make rapid and accurate diagnoses on small biopsy specimens.
Diagnostic acumen is no longer sufficient, according to NeoGenomics, Fort Myers, Fla, adding that in this age of personalized medicine, pathologists must triage these small samples to the appropriate ancillary molecular assays in order to ensure that patients get the best available targeted therapy.
The company is hosting a live Webinar on September 27, at 2 to 3 pm EDT, where Barbara Chaitin, MD, NeoGenomics medical director, will focus on two of the most prevalent cancers: non-small cell lung carcinoma and colorectal cancer. She will present the most updated practice guidelines in oncology from the National Cancer Center Network (NCCN) and discuss the pathologist’s role in molecular testing strategies, including EGFR, KRAS, and ALK testing in NSCLC, KRAS/BRAF testing in colorectal cancer, and screening for Lynch Syndrome in colon cancer specimens.
- Lung cancer classification
- KRAS, EGFR, ALK
- Non-small cell lung cancer (NSCLC) NCCN practice guidelines
- What’s new- ROS1
- Colon cancer classification
- Lynch Syndrome (HNPCC) testing
- Colorectal NCCN practice guidelines
Click here to register.
PC-based attendees need: Windows® 7, Vista, XP or 2003 Server
Macintosh®-based attendees need: Mac OS® X 10.5 or newer
Mobile attendees need: Required: iPhone®/iPad®/Android™ smartphone or tablet
Chaitin attended Albert Einstein College of Medicine, completed her anatomic and clinical pathology residency at University of California in San Francisco, and completed fellowships in surgical pathology at Stanford University Medical Center and at MD Anderson Cancer Center. She is board certified in forensic pathology and anatomic pathology.
[Source: NeoGenomics Laboratories]